Pulse Biosciences(PLSE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PLSE Pulse Biosciences

Post-Mkt 04-16 16:15:43 EDT

20.51

+0.87

+4.40%

盘后20.51

+0.000.00%

16:10 EDT

High20.69	Low19.75	Vol293.18K
Open19.91	D1 Closing19.65	Amplitude4.81%
Mkt Cap1.39B	Tradable Cap357.66M	Total Shares67.77M
T/O5.96M	T/O Rate1.68%	Tradable Shares17.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PLSE","market":"US","secType":"STK","nameCN":"Pulse Biosciences","latestPrice":20.51,"timestamp":1776369600000,"preClose":19.645,"halted":0,"volume":293183,"hourTrading":{"tag":"盘后","latestPrice":20.51,"preClose":20.51,"latestTime":"16:10 EDT","volume":1616,"amount":33144.16,"timestamp":1776370204508,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.044031560193433544,"floatShares":17438312,"shares":67767578,"eps":-1.079911,"marketStatus":"Post-Mkt","change":0.865,"latestTime":"04-16 16:15:43 EDT","open":19.91,"high":20.69,"low":19.745,"amount":5960775.71325,"amplitude":0.048104,"askPrice":25.8,"askSize":100,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.079911,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776384000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1463544000000,"exchange":"NASDAQ","adjPreClose":19.645,"postHourTrading":{"tag":"盘后","latestPrice":20.51,"preClose":20.51,"latestTime":"16:10 EDT","volume":1616,"amount":33144.16,"timestamp":1776370204508,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.358743,"impliedVol":0.845,"impliedVolPercentile":0.888},"requestUrl":"/m/hq/s/PLSE/wiki","defaultTab":"wiki","newsList":[{"id":"2628217722","title":"Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche","url":"https://stock-news.laohu8.com/highlight/detail?id=2628217722","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628217722?lang=en_us&edition=fundamental","pubTime":"2026-04-17 00:32","pubTimestamp":1776357157,"startTime":"0","endTime":"0","summary":"Pulse Biosciences Inc ($PLSE) announced an update on their ongoing clinical study. The PRECISE-BTN study is a prospective trial run by Pulse Biosci...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-targets-thyroid-nodules-with-new-device-study-eyeing-a-minimally-invasive-niche?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-targets-thyroid-nodules-with-new-device-study-eyeing-a-minimally-invasive-niche?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627569219","title":"Pulse Biosciences Updates 2026 Cardiac Ablation Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2627569219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627569219?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:55","pubTimestamp":1776347737,"startTime":"0","endTime":"0","summary":"Pulse Biosciences ( ($PLSE) ) has shared an update. On April 16, 2026, Pulse Biosciences posted an updated investor presentation detailing its pivo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-updates-2026-cardiac-ablation-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-updates-2026-cardiac-ablation-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626170540","title":"Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626170540","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626170540?lang=en_us&edition=fundamental","pubTime":"2026-04-12 19:18","pubTimestamp":1775992696,"startTime":"0","endTime":"0","summary":"Pulse Biosciences recently expanded its leadership team, appointing Liane Teplitsky as Chief Operating Officer and increasing Dr. David Kenigsberg’s role as full-time Chief Medical Officer to accelerate development and future commercialization of the nPulse Cardiac Catheter Ablation System for atrial fibrillation.\nThese leadership moves follow the first patient enrollments in the pivotal NANOPULSE-AF study, underscoring the company’s focus on turning its nanosecond pulsed field ablation...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/is-pulse-biosciences-new-leadership-structure-reframing-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/is-pulse-biosciences-new-leadership-structure-reframing-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626826189","title":"BRIEF-Pulse Biosciences Strengthens Executive Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2626826189","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626826189?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:11","pubTimestamp":1775733077,"startTime":"0","endTime":"0","summary":"BRIEF-Pulse Biosciences Strengthens Executive Leadership TeamPulse Biosciences Inc PLSE.O:PULSE BIOSCIENCES STRENGTHENS EXECUTIVE LEADERSHIP TEAMSource text: ID:nBwb5cT6saFurther company coverage: PLSE.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA5PK2GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186462","title":"Pulse Biosciences names Liane Teplitsky chief operating officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186462","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186462?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:02","pubTimestamp":1775732540,"startTime":"0","endTime":"0","summary":"Pulse Biosciences appointed Liane Teplitsky as chief operating officer to oversee clinical, regulatory, quality, commercial functions tied to nPulse Cardiac Catheter Ablation System.Teplitsky most recently served as CEO of Artedrone, leading development of autonomous robotic technology for stroke treatment.Her prior roles included senior marketing, commercial leadership positions at Abbott Laboratories, St. Jude Medical, roles focused on cardiovascular, electrophysiology therapies.Pulse expanded David Kenigsberg’s role to full-time chief medical officer while he maintains routine clinical practice.Kenigsberg will lead clinical strategy as Pulse advances IDE pivotal study of nPulse Cardiac Catheter System for atrial fibrillation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL1fmfsD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","LU1914381329.SGD","SG9999002232.USD","BK4082","LU2324357040.USD","LU2112291526.USD","LU1057294990.SGD","BK4504","BK4581","LU1721429402.USD","IE00B2B36J28.USD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2237957811.SGD","LU0868494617.USD","SG9999002224.SGD","BK4585","LU1989763690.USD","IE00BFTCPJ56.SGD","PLSE","LU0882574055.USD","LU2089984988.USD","ABT","IE0002141913.USD","BK4592","LU2468319806.SGD","LU2133065610.SGD","SGXZ23171101.USD","LU2237957902.USD","LU0266013472.USD","LU0234572021.USD","BK4566","LU1721429741.USD","LU1691799644.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","BK4568","LU0114720955.EUR","LU1989763427.SGD","BK4588","BK4533","LU0289739699.SGD","LU0122379950.USD","LU0170899867.USD","SGXZ41872573.SGD","LU2211815571.USD","LU1023059063.AUD","SG9999004303.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626903847","title":"Affluent Medical names Anne Lange to board, replaces Soad El Gazaoui","url":"https://stock-news.laohu8.com/highlight/detail?id=2626903847","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626903847?lang=en_us&edition=fundamental","pubTime":"2026-04-09 13:31","pubTimestamp":1775712683,"startTime":"0","endTime":"0","summary":"Affluent Medical, now operating as Carvolix, appointed Anne Lange to board of directors on April 9, replacing outgoing director Soad El Gazaoui.Lange brings board experience at Pernod Ricard, Orange, and Peugeot Invest, with prior senior roles at Cisco and in French government.Carvolix named Rute Fernandes as board observer; she previously held senior leadership roles at Takeda, Shire, and Novartis, including country president and general manager of Canada.Board leadership structure shifted with Liane Teplitsky confirmed as chair, Michel Therin appointed vice chair.Advisory board expanded with Paul LaViolette, CEO and co-chairman of Pulse Biosciences and managing partner at SV Health Investors, plus interventional cardiologist Dr. Mirvat Alasnag of King Fahad Armed Forces Hospital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL7YNY0j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625022955","title":"Pulse Biosciences Launches Pivotal NANOPULSE-AF Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2625022955","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625022955?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:31","pubTimestamp":1775568675,"startTime":"0","endTime":"0","summary":"Pulse Biosciences ( ($PLSE) ) has provided an announcement. On April 7, 2026 Pulse Biosciences announced it had enrolled and treated the first seve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-launches-pivotal-nanopulse-af-clinical-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-launches-pivotal-nanopulse-af-clinical-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932319","title":"Pulse Biosciences enrolls first patients in NANOPULSE-AF pivotal trial for AF ablation system","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932319","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932319?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559658,"startTime":"0","endTime":"0","summary":"Pulse Biosciences began enrolling patients in NANOPULSE-AF, an IDE pivotal study testing its nPulse cardiac catheter system for recurrent, drug-resistant symptomatic paroxysmal atrial fibrillation.First seven patients were treated at St. Bernards Medical Center in Arkansas, marking start of planned expansion to as many as 30 sites in US and Europe.Prior first-in-human feasibility results have already been presented, supporting further development of nanosecond pulsed field ablation as a differentiated approach to atrial fibrillation procedures.Program aims to confirm durable rhythm control with streamlined procedures while reducing unintended effects on nearby heart structures, based on earlier clinical experience.System is integrated with Abbott EnSite X mapping software, positioning the platform for broader adoption if pivotal data support safety and effectiveness.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT stri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLT0Rxq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625321932","title":"Pulse Biosciences Enrolls First Patients in Nanopulse-Af Ide Pivotal Clinical Study Evaluating Npulse™ Cardiac Catheter System for Atrial Fibrillation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625321932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625321932?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA40BBDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624810632","title":"Is It Too Late To Consider Pulse Biosciences (PLSE) After Recent Share Price Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624810632","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624810632?lang=en_us&edition=fundamental","pubTime":"2026-04-03 11:33","pubTimestamp":1775187219,"startTime":"0","endTime":"0","summary":"Investors may be wondering whether Pulse Biosciences, at around US$23 per share, still offers value or whether most of the opportunity is already reflected in the price.\nThe stock shows returns of 7.0% over 7 days, 28.1% over 30 days, 71.8% year to date and 58.3% over 1 year. These figures naturally raise questions about what is already priced in and how much risk you are taking on at current levels.\nRecent attention on Pulse Biosciences has centered on its position in the medical equipment...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/is-it-too-late-to-consider-pulse-biosciences-plse-after-rece","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/is-it-too-late-to-consider-pulse-biosciences-plse-after-rece","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624828346","title":"Pulse Biosciences to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2624828346","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624828346?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:06","pubTimestamp":1775160363,"startTime":"0","endTime":"0","summary":"Pulse Biosciences to present at 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, at 9:30 a.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire  on April 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL5dRLq0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622805294","title":"Pulse Biosciences Grants RSUs to Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622805294","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622805294?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:43","pubTimestamp":1774647814,"startTime":"0","endTime":"0","summary":"Pulse Biosciences ( ($PLSE) ) has provided an update. On March 23, 2026, Pulse Biosciences, Inc. granted its Chief Technology Officer, Darrin R. Ue...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-grants-rsus-to-chief-technology-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-grants-rsus-to-chief-technology-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808459","title":"Pulse Biosciences awards CTO Darrin R. Uecker 100,000 restricted stock units; grant vests in full on third anniversary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808459","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808459?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:33","pubTimestamp":1774643616,"startTime":"0","endTime":"0","summary":"Pulse Biosciences’ compensation committee awarded Chief Technology Officer Darrin R. Uecker restricted stock units representing 100,000 common shares.The restricted stock units are scheduled to vest in full on the third anniversary of the grant date, subject to the award agreement and the Amended and Restated 2017 Equity Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL4810Xn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621674571","title":"Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot","url":"https://stock-news.laohu8.com/highlight/detail?id=2621674571","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621674571?lang=en_us&edition=fundamental","pubTime":"2026-03-23 01:07","pubTimestamp":1774199235,"startTime":"0","endTime":"0","summary":"Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and conference presentations.\nSee our latest analysis for Pulse Biosciences.\nThese AFib data and the new focus on the nPulse Cardiac Catheter program come after a strong run, with a 90 day share price return of 45.39% and a very large 3 year total shareholder return. At the same time, the 1 year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-the-npulse","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-the-npulse","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620216544","title":"BRIEF-Pulse Biosciences Announces Strategic Alignment To Accelerate Cardiac Catheter Program Following Exceptional Long-Term Afib Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2620216544","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620216544?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:53","pubTimestamp":1773748436,"startTime":"0","endTime":"0","summary":"BRIEF-Pulse Biosciences Announces Strategic Alignment To Accelerate Cardiac Catheter Program Following Exceptional Long-Term Afib Clinical DataMarch 17 (Reuters) - Pulse Biosciences Inc PLSE.O:PULSE B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nFWN4040ZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426949","title":"Pulse Biosciences prioritizes R&D and clinical investment for its nPulse cardiac catheter pivotal IDE studies in the US and Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426949?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:01","pubTimestamp":1773745280,"startTime":"0","endTime":"0","summary":"Pulse Biosciences prioritizes R&D and clinical investment for its nPulse cardiac catheter pivotal IDE studies in the US and Europe. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire  on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL596Pw4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618136354","title":"Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2618136354","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618136354?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313243,"startTime":"0","endTime":"0","summary":"Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma. Pulse Biosciences reported the first patient enrollments in a multicenter, first-in-human feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma. The prospective study plans to enroll 30 patients across two sites and includes tumors smaller than 1.5 cm. Initial procedures were completed at Sarasota Memorial Health Care System and UT MD Anderson Cancer Center, with Ralph P. Tufano and Victoria Banuchi involved in the first cases. The device is being evaluated for thyroid cancer use under an FDA Investigational Device Exemption, and no study results were reported in the announcement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL7j2DZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618135075","title":"Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors With Npulse™ Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618135075?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA24PDSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLSE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618606922","title":"Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2618606922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618606922?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:27","pubTimestamp":1773102435,"startTime":"0","endTime":"0","summary":"Pulse Biosciences Inc (($PLSE)) has held its Q4 earnings call. Read on for the main highlights of the call. Pulse Biosciences’ latest earnings call...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-earnings-call-data-strength-vs-cash-burn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-earnings-call-data-strength-vs-cash-burn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618976624","title":"Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976624","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976624?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:57","pubTimestamp":1773064651,"startTime":"0","endTime":"0","summary":"An update from Pulse Biosciences ( ($PLSE) ) is now available. On March 9, 2026, Pulse Biosciences reported long-term clinical durability data from...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-reports-durable-thyroid-nodule-ablation-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulse-biosciences-reports-durable-thyroid-nodule-ablation-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","PLSE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pulsebiosciences.com","stockEarnings":[{"period":"1week","weight":0.0307},{"period":"1month","weight":-0.1001},{"period":"3month","weight":0.3933},{"period":"6month","weight":0.1187},{"period":"1year","weight":0.1536},{"period":"ytd","weight":0.4308}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.039406},{"month":2,"riseRate":0.4,"avgChangeRate":0.027622},{"month":3,"riseRate":0.4,"avgChangeRate":0.019181},{"month":4,"riseRate":0.5,"avgChangeRate":0.101931},{"month":5,"riseRate":0.333333,"avgChangeRate":0.00138},{"month":6,"riseRate":0.5,"avgChangeRate":0.006609},{"month":7,"riseRate":0.5,"avgChangeRate":0.013289},{"month":8,"riseRate":0.6,"avgChangeRate":0.001957},{"month":9,"riseRate":0.5,"avgChangeRate":0.125621},{"month":10,"riseRate":0.3,"avgChangeRate":0.008129},{"month":11,"riseRate":0.5,"avgChangeRate":0.107856},{"month":12,"riseRate":0.6,"avgChangeRate":0.087874}],"exchange":"NASDAQ","name":"Pulse Biosciences","nameEN":"Pulse Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pulse Biosciences(PLSE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pulse Biosciences(PLSE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pulse Biosciences,PLSE,Pulse Biosciences股票,Pulse Biosciences股票老虎,Pulse Biosciences股票老虎国际,Pulse Biosciences行情,Pulse Biosciences股票行情,Pulse Biosciences股价,Pulse Biosciences股市,Pulse Biosciences股票价格,Pulse Biosciences股票交易,Pulse Biosciences股票购买,Pulse Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pulse Biosciences(PLSE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pulse Biosciences(PLSE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction